NCT01230021View on ClinicalTrials.gov

Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency

PHASE3CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Congenital Bleeding DisorderCongenital FXIII Deficiency
Interventions
DRUG

catridecacog

Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg bodyweight

Trial Locations (10)

43205

Novo Nordisk Investigational Site, Columbus

48201

Novo Nordisk Investigational Site, Detroit

49100

Novo Nordisk Investigational Site, Petah Tikva

55404

Novo Nordisk Investigational Site, Minneapolis

02115

Novo Nordisk Investigational Site, Boston

B4 6NH

Novo Nordisk Investigational Site, Birmingham

LE1 5WW

Novo Nordisk Investigational Site, Leicester

M13 9WL

Novo Nordisk Investigational Site, Manchester

NE1 4LP

Novo Nordisk Investigational Site, Newcastle upon Tyne

RG1 5AN

Novo Nordisk Investigational Site, Reading

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY